

Corresponding author(s):	Tae-Hee Kim
Last updated by author(s):	Aug 25, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

<u> </u>			
St	at	isti	Γ

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection No software was used for data collection

Data analysis Read trimming: trimmomatic v0.32

Genome alignment: STAR v2.5.1b Gene-level counting: featureCounts v1.5.0

Differential expression analysis: DESeq2 v1.14.1

GO Enrichment: gProfiler rev 1741 build date 2017-10-19

Enrichment Map of GO terms: cytoscape v3.6.0 using the EnrichmentMap app v2.0.1

A custom R/Sweave script integrating the above analysis will be submitted with example data.

ImageJ for image analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

RNA-seq data generated in this study have been deposited in GEO under the accession GSE123136.

Raw fastq data is available in SRA under the accession SRP171166.

Source data underlying Figure 1b-d, 5b, and Supplementary Figure 1b-d are included as a Source Data File.

~ ~	, , , , ,	plementary Tables 3+4) ticle, in the supplementary files, or from the corresponding author upon	
ield-spe	ecific reporting		
lease select the o	e one below that is the best fit for your research. If you are not s	ure, read the appropriate sections before making your selection.	
Life sciences	Behavioural & social sciences Ecologica	l, evolutionary & environmental sciences	
or a reference copy of t	of the document with all sections, see nature.com/documents/nr-reporting-sumn	ary-flat.pdf	
ife scier	ences study design		
ll studies must dis	disclose on these points even when the disclosure is negative.		
Sample size	Sample size was dependent on litter sizes produced from genetic crosses. A minimum sample number of 3 was used for all analyses of genetic mouse models.		
Data exclusions	No data was excluded		
Replication	Bulk mRNA-seq for E13.5 stomach, pancreas, intestine, and mutants: 2 replicates each. PCA analysis demonstrated strong clustering between replicates.		
Randomization	This study does not contain groups that require randomization.		
Blinding	Samples were analyzed in random order. However, due to the dramatic phenotypes observed in our mutants, complete blinding was not always possible.		
Ve require informati		ems and methods s and methods used in many studies. Here, indicate whether each material, o your research, read the appropriate section before selecting a response.	
Materials & ex	experimental systems Methods		
ı/a Involved in th	the study n/a Involved in the study		
Antibodies	lies ChIP-seq		
	otic cell lines Flow cytometry		
Palaeontol		aging	
	and other organisms research participants		
Clinical dat			

Antibodies

Antibodies used

mouse anti-insulin (Sigma, 12018), rabbit anti-insulin (Abcam, ab181547), rabbit anti-amylase (Abcam, ab21156), mouse antiglucagon (Abcam, ab10988), mouse anti-smooth muscle actin (Sigma, A2547), rabbit anti-desmin (Abcam, ab32362), rabbit anti-SM22 (Abcam, ab14106), mouse anti-PDX1 (DSHB, F109-D12), rabbit anti-SOX2 (Abcam, ab97959), rat anti-BrDU (Abcam, 6326), rabbit anti-SOX9 (EMD Millipore, AB5535), mouse anti-NGN3 (DSHB, F25A1B3), mouse anti-NKX6.1 (DSHB, F55A12), rat anti-somatostatin [M09204] (Abcam, ab30788), rat anti-ghrelin (R&D systems, MAB8200), mouse anti-EpCam [G8.8] (DSHB, G8.8). Secondary antibodies: AlexaFlour488 and AlexFlour568.

Validation

mouse anti-insulin (Sigma, I2018), rabbit anti-insulin (Abcam, ab181547), rabbit anti-amylase (Abcam, ab21156), mouse antiglucagon (Abcam, ab10988), mouse anti-smooth muscle actin (Sigma, A2547), rabbit anti-desmin (Abcam, ab32362), rabbit anti-SM22 (Abcam, ab14106), rabbit anti-SOX2 (Abcam, ab97959), rat anti-BrDU (Abcam, 6326), rabbit anti-SOX9 (EMD Millipore, AB5535), rat anti-somatostatin [M09204] (Abcam, ab30788), rat anti-ghrelin (R&D systems, MAB8200) were all validated by the supplier.

For mouse anti-PDX1 (DSHB, F109-D12), mouse anti-NGN3 (DSHB, F25A1B3), mouse anti-NKX6.1 (DSHB, F55A12), mouse anti-EpCam [G8.8] (DSHB, G8.8) from DSHB, see company website for originating publication of the antibody. All antibodies were tested on control pancreatic tissue prior to use for experiments.

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

H1 embryonic stem cell - WiCell Research Institute (Madison WI, USA): BJ-iPSC-1 induced pluripotent stem cell line - Drs. Toshi Araki and Ben Neel (New York University, NY, USA). Dr. Nostro has approval from the Stem Cell Oversight Committee (Canadian Institute of Health Research) to conduct work with SCOC-approved H1 and human iPSCs

Authentication

Cell lines were karyotyped upon receipt to check for the presence of abnormal chromosomes

Mycoplasma contamination

Cell lines were tested and negative for mycoplasma contamination

Commonly misidentified lines (See ICLAC register)

No commonly misidentified lines used in this study.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Bapx1Cre, ROSA26(mT/mG), Pdx1Cre, Sufuf/f, Spopf/f, Gli2f/f, Smof/f, and CD-1 mice Laboratory animals

Wild animals Our study did not involve wild animals.

Field-collected samples Our study did not involve samples collected from the field.

Ethics oversight All procedures involving animals were performed in compliance with the Animals for Research Act of Ontario and the Guidelines of the Canadian Council on Animal Care. The Toronto Centre for Phenogenomics (TCP) Animal Care Committee reviewed and

approved all procedures conducted on animals at TCP

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Murine embryonic gut tissue: Trypsin digestion at 37C, manual homogenization, stained with SYTOX Blue Dead Cell Stain, filtered Sample preparation prior to sorting.

Instrument Beckman Coulter Mo Flo XDP, Mo Flo Astrios sorter, or Sony SH800S Cell Sorter

Software FlowJo (version 9.8.3)

Cell population abundance GFP+ mesenchymal cells at E15.5: 40% of live cells

Gating strategy Debris excluded by FSC-A vs. BSC-A. Doublets excluded by FSC-W vs. FSC-H. Live cells were gated using SYTOX Blue Dead Cell Stain. GFP+/- was determined using GFP negative embryo or unstained controls from the same batch of samples.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.